Adenosine as an adjunct to reperfusion in myocardial infarction

European Heart Journal

Volumn 27, Issue 20, 2006, Pages 2376-2377

  Maurer, Gerald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; PLACEBO;

ANGIOPLASTY; BLOOD CLOT LYSIS; BRADYCARDIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; HYPOTENSION; POST HOC ANALYSIS; PRIORITY JOURNAL; TIME;

ADENOSINE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; VASODILATOR AGENTS;

EID: 33749504461     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl268     Document Type: Editorial

References (10)

1. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21:537-545.
2. Mangano DT, Miao Y, Tudor IC, Dietzel C. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol 2006;48:206-214.
3. Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischaemic-reperfused hearts. Am J Physiol Heart Circ Physiol 2003;285:H1797-H1818.
4. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987;76:1135-1145.
5. ATP channels. Circulation 1994;89:1226-1236.
6. Yang X-M, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires P13-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100:57-63.
7. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB, for the AMISTAD investigators. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-1720.
8. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, for the AMISTAD II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTADII). J Am Coll Cardiol 2005;45:1775-1780.
9. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006;27:2400-2405. First published on June 16, 2006, doi: 10.1093/eurheartj/ehl094.
10. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56.